Abstract | STUDY OBJECTIVE: METHODS: Patients admitted to 48 US hospitals within the Pediatric Health Information System between January 2008 and December 2016 with associated International Classification of Diseases, Ninth Revision (ICD-9) or ICD-10 diagnoses of SCD and acute chest syndrome were included. Primary outcomes were hospital length of stay and acute chest syndrome-related and all-cause 30-day readmission. Data were analyzed with t tests, ANOVA, and bivariable and multivariable linear and logistic regressions. RESULTS: In 21,126 visits (representing 8,856 patients), median age was 11.2 years (interquartile range 6.1 to 16.5 years), 53.5% were male patients, and 77.2% had hemoglobin SS genotype. Median length of stay was 4 days (interquartile range 2 to 6 days; mean 4.76 days [SD 4.62 days]). Ceftriaxone alone ( length of stay 4.75 days [SD 4.66 days]; P<.001) or the combination of ceftriaxone and azithromycin ( length of stay 4.84 days [SD 4.74 days]; P<.001) was associated with the shortest length of stay and a reduced risk of acute chest syndrome-related readmission ( ceftriaxone odds ratio [OR] 0.31; 95% confidence interval [CI] 0.27 to 0.35; ceftriaxone+azithromycin OR 0.20; 95% CI 0.17 to 0.24). Albuterol (OR 0.97; 95% CI 0.96 to 0.98) and RBC transfusion (OR 0.60; 95% CI 0.43 to 0.83) were also associated with decreased rates of acute chest syndrome-related 30-day readmission. All-cause 30-day readmission rate was 16.7% (95% CI 16.2% to 17.3%). CONCLUSION:
|
Authors | Oluwakemi Badaki-Makun, James F Casella, Sean Tackett, Xueting Tao, James M Chamberlain |
Journal | Annals of emergency medicine
(Ann Emerg Med)
Vol. 76
Issue 3S
Pg. S37-S45
(09 2020)
ISSN: 1097-6760 [Electronic] United States |
PMID | 32928460
(Publication Type: Journal Article, Observational Study)
|
Copyright | Copyright © 2020 American College of Emergency Physicians. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Anti-Bacterial Agents
- Cephalosporins
- Macrolides
|
Topics |
- Acute Chest Syndrome
(drug therapy, etiology)
- Adolescent
- Anemia, Sickle Cell
(complications, drug therapy)
- Anti-Bacterial Agents
(therapeutic use)
- Cephalosporins
(therapeutic use)
- Child
- Female
- Humans
- Length of Stay
(statistics & numerical data)
- Linear Models
- Logistic Models
- Macrolides
(therapeutic use)
- Male
- Patient Readmission
(statistics & numerical data)
- Retrospective Studies
- Risk Factors
- United States
|